Satellos to Participate in November 2024 Investor Conferences
Format: Fireside Chat
Date:
Format: Presentation
Date:
Format: Participation in 1x1 meetings
Dates:
The fireside chat and presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the events.
About
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX™, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104187364/en/
Investors:
Media:
Source:
